AngioDynamics (ANGO) Tops Q4 EPS by 9c, provides guidance

AngioDynamics (NASDAQ: ANGO) reported Q4 EPS of ($0.03), $0.09 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $80.2 million versus the consensus estimate of $74.27 million.

GUIDANCE:

AngioDynamics sees FY2026 EPS of ($0.35)-($0.25), versus the consensus of ($0.23). AngioDynamics sees FY2026 revenue of $305-310 million, versus the consensus of $304.9 million.

For earnings history and earnings-related data on AngioDynamics (ANGO) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Real and RE/MAX Holdings receive court approval for merger
• Is the global equity rally broadening? UBS weighs in